Skip to content

Explore the sensitive population of Shentao Ruangan granule in the treatment of primary liver cancer, an observational study

Explore the sensitive population of Shentao Ruangan granule in the treatment of primary liver cancer, an observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074519
Enrollment
Unknown
Registered
2023-08-09
Start date
2023-08-10
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary liver cancer

Interventions

Observation group ( On the basis of conventional anti-tumor treatment, Shentao Ruangan Granule will be used according to the condition ):NA

Sponsors

The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: ? Pathological or clinical diagnosis of primary liver cancer according to the criteria of China Society of Clinical Oncology (CSCO) Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2020); ? Age 18 years and above. ? The expected survival is more than 3 months. ? EORTC QLQ-HCC18 scale score =21 points. ? No major organ disease, heart (NYHA cardiac function = Class II), liver (bilirubin <1.5 times of normal, aspartate aminotransferase and alanine aminotransferase <3 times of normal), kidney (creatinine < 180umol/L) function was basically normal.

Exclusion criteria

Exclusion criteria: ? Patients with severe cardiovascular and cerebrovascular diseases, kidney diseases, hematopoietic system and other primary diseases and psychosis. ? There were severe complications, such as gastrointestinal bleeding or obstruction. ? Pregnant or lactating women. ? Patients with multiple cancers. ? Patients with poor compliance, unable to take medicine according to regulations and unable to cooperate with the follow-up.

Design outcomes

Primary

MeasureTime frame
EORTC QLQ-HCC18 scale ;

Secondary

MeasureTime frame
Primary liver cancer TCM syndrome scale;Tongue picture characteristic table;Pulse characteristic table;

Countries

China

Contacts

Public ContactZhou Daihan

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

13602776166@139.com+86 139 0220 6571

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026